US health regulator (USFDA) has given its approval to Aurobindo Pharma to market their heart disease drug Eptifibatide Injection. This drug is basically used in the treatment of acute coronary syndrome, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Eptifibatide Injection. This product is expected to be launched in this month.
The Hyderabad-based firm's product is therapeutically equivalent to Schering Corporation's Integrilin injection.Eptifibatide Injection is used in the treatment of acute coronary syndrome. According to IMS data, the approved product had an estimated market size of USD 137 million for the 12 months ending October 2015.
Aurobindo now has 18 abbreviated new drug application ANDAs approved out of Unit IV formulation facility in Hyderabad.
The company has a total of 222 ANDA approvals, including 10 from Aurolife Pharma LLCand 28 tentative approvals from USFDA.
View Latest News:
- Union Fertilisers Minister Ananth Kumar Announces Formation of Separate Ministry for Pharma in Next One Year
- After 20 Years of Research the World's First Dengue Vaccine Dengvaxia Finally Receives Approval
- Gene Activity in Cancer Stem Cells Can Now be Altered By Agents Delivered By Nanobombs
- BioPharma Companies and Medical Sectors Receive New Funds